OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Harrison on the Current State of Treatment in Myelofibrosis

December 1st 2021

Claire Harrison, MD, FRCP, FRCPath, discusses the current state of treatment in myelofibrosis.

Dr. Chen on Risk Factors for Developing cGVHD

December 1st 2021

Yi-Bin Chen, MD, discusses risk factors for developing chronic graft-vs-host disease in patients who receive an allogeneic transplant.

Dr. Neumann on Tapering Steroids in cGVHD

December 1st 2021

Joyce L. Neumann, PhD, APRN, AOCN, BMTCN, FAAN, discusses tapering steroids for patients with chronic graft-vs-host disease.

Fellows on Film: How To Market Yourself for a Fellowship

November 30th 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to market oneself for a fellowship in oncology.

Fellows on Film: How to Be a Good Mentor for Fellows

November 30th 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss how to be a good mentor for fellows in oncology.

Fellows on Film: The Importance of Having a Mentor

November 30th 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss the importance of having a mentor during fellowship.

Dr. Allison on the Impact of Immunotherapy in Cancer

November 30th 2021

James P. Allison, PhD, discusses the impact of immunotherapy on patients with cancer.

Dr. Allison on the Development of Ipilimumab for Cancer Treatment

November 30th 2021

James P. Allison, PhD, discusses the development of ipilimumab.

Dr. Shah on the Significance of PARP Inhibitors in Ovarian Cancer

November 30th 2021

Payal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.

Dr. Bordoni on the Utility of Adjuvant Atezolizumab in the Adjuvant Setting in NSCLC

November 30th 2021

Rodolfo Bordoni, MD, discusses the utility of atezolizumab in the adjuvant setting in non–small cell lung cancer.

Dr. Allison on His Early Career at The University of Texas MD Anderson Cancer Center

November 29th 2021

James P. Allison, PhD, discusses his early career at The University of Texas MD Anderson Cancer Center.

Dr. Allison on Reverse Translation in Cancer Research

November 29th 2021

James P. Allison, PhD, discusses his research on reverse translation in cancer.

What Can Residents Learn From an Oncology Fellowship?

November 25th 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what the benefits are of an oncology fellowship and the takeaways and important lessons Nardello learned from his own breast oncology fellowship at Fox Chase Cancer Center.

Why Should Someone Pursue a Fellowship in Oncology?

November 25th 2021

Richard J. Bleicher, MD, FACS, and Salvatore Nardello, DO, discuss what brought Dr. Nardello to the breast cancer field, what made him decide to pursue an oncology fellowship, and what residents should think about when choosing a fellowship location.

Dr. Shah and Dr. Wang on the Need for Academic and Community Collaboration With CAR T-Cell Therapy

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the need for collaboration between academic and community practices for patients who receive CAR T-cell therapy.

Dr. Shah and Dr. Wang on the Challenges of Managing High-Risk MCL

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the challenges of managing high-risk mantle cell lymphoma.

Dr. Shah and Dr. Wang on Navigating the Referral Process for CAR T-Cell Therapy in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss navigating the referral process for CAR T-cell therapy in hematologic malignancies.

Dr. Shah and Dr. Wang on Managing CRS and Neurotoxicity in Leukemia/Lymphoma

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss management strategies for CAR T-cell therapy–related cytokine release syndrome and neurotoxicity in leukemia and lymphoma.

Dr. Shah and Dr. Wang on CAR T-Cell Therapy–Associated Toxicities in Hematologic Malignancies

November 24th 2021

Bijal Shah, MD, MS, and Michael Wang, MD, discuss the main CAR T-cell therapy–associated toxicities in hematologic malignancies.

Dr. Leal on Developments Made in EGFR Exon 20–Mutant NSCLC Treatment

November 24th 2021

Ticiana Leal, MD, discusses developments made in the treatment of patients with EGFR exon 20 insertion–mutant non–small cell lung cancer.